Placeholder

Mianserin

CAS No:
24219-97-4 Category:
  • # LGM Pharma is a Mianserin CAS# 24219-97-4 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, samples, sourcing, purity and more.
  • # Questions? Call our customer API support number 1-(800)-881-8210.
  • # LGM Pharma offers this active ingredient but not the finished dosage forms.
  • Inquire about this product >>

Product Details:

  • Product Name: Mianserin
  • CAS #: 24219-97-4
  • Mode of Action:

    Mianserin's mechanism of therapeutic action is not well understood, although it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors.

  • Pharmacodynamics:

    Mianserin is a tetracyclic antidepressant that has antihistaminic and hypnosedative, but almost no anticholinergic, effect. It is a weak inhibitor of norepinephrine reuptake and strongly stimulates the release of norepinephrine. Interactions with serotonin receptors in the central nervous system have also been found. Its effect is usually noticeable after one to three weeks. Mianserin may cause drowsiness and hematological problems.

  • Metabolism:

    Hepatic.

  • Toxicity:

    Oral rat LD50: 780mg/kg

  • IUPAC: 5-methyl-2, 5-diazatetracyclo[13.4.0.0, {2, 7}.0, {8, 13}]nonadeca-1(15), 8(13), 9, 11, 16, 18-hexaene
  • ATC: N06AX03
  • PubChem: 4184
  • DrugBank: DB06148
  • Formula: C8H17NO5
  • Molecular Mass: 264.3648
  • Synonyms: Mianserina [inn-spanish] Mianserine Mianserine [inn-french] Mianserinum [inn-latin] Mianseryna [polish]
  • SMILES: CN1CCN2C(C1)C1=CC=CC=C1CC1=CC=CC=C21
  • InChl: UEQUQVLFIPOEMF-UHFFFAOYSA-N
  • General Reference:

    1. Koyama E, Chiba K, Tani M, Ishizaki T: Identification of human cytochrome P450 isoforms involved in the stereoselective metabolism of mianserin enantiomers. J Pharmacol Exp Ther. 1996 Jul;278(1):21-30. Pubmed
    2. de Boer TH, Nefkens F, van Helvoirt A, van Delft AM: Differences in modulation of noradrenergic and serotonergic transmission by the alpha-2 adrenoceptor antagonists, mirtazapine, mianserin and idazoxan. J Pharmacol Exp Ther. 1996 May;277(2):852-60. Pubmed
    3. Kelder J, Funke C, De Boer T, Delbressine L, Leysen D, Nickolson V: A comparison of the physicochemical and biological properties of mirtazapine and mianserin. J Pharm Pharmacol. 1997 Apr;49(4):403-11. Pubmed

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Streamlined API supply towards initial research stages as well as larger quantities of cGMP material for clinical trials and product commercialization
  • Premium quality GMP certified and fully accredited API manufacturing plants

 

  • Technical packages as well as access to filed DMF,
    ASMF or CEP (subject to availability)
  • Regulatory and technical assistance towards any
    submission type based on specific customer requirements
This website uses cookies. By using our site, you agree to our terms of service